EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beta-Thalassemia: A Pharmacological Drug-Based Treatment

Shrabonti Biswas, Shanita Zaman Smrity, Md. Shimul Bhuia, Fatema Akter Sonia, Mst. Asma Aktar, Raihan Chowdhury, Tawhida Islam, Muhammad Torequl Islam, Gabriel Gonçalves Alencar, Cicera Laura Roque Paulo, Ana Pavla Almeida Diniz Gurgel, Henrique Douglas Melo Coutinho

Drugs and Drug Candidates · 08.02.2024 · 3 (1) · 126-147

DOI: 10.3390/ddc3010008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 08.02.2024. Verfasst von Shrabonti Biswas und 11 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review was performed to determine the potential of drugs that can remove or decrease the requirements for blood transfusion among beta (β)-thalassemia patients. A comprehensive literature search was conducted to identify clinical trials and studies using PubMed Central, Google Scholar, PubMed, and ScienceDirect archived articles published from 1996 to November 2023. According to this review, clinical trials for a number of drugs, including luspatercept, sotatercept, mitapivat, etavopivat, hydroxyurea, rapamycin, decitabine, thalidomide, and quercetin, have been performed as part of efforts to improve the cure strategy for β-thalassemia. Of these drugs, luspatercept and sotatercept have exhibited particularly promising results and have been granted US Food and Drug Administration (FDA) approval for use in β-thalassemia patients. The mode of action for the drugs luspatercept and sotatercept involves the stimulation of hemoglobin (Hb) production or enhancement of its functionality, thereby decreasing reliance on blood transfusions and enhancing the overall quality of life. In this way, drugs like luspatercept and sotatercept present an opportunity to notably decrease the necessity for blood transfusions in β-thalassemia patients, improving their standard of living and overall prognosis. However, more research is needed to evaluate the effectiveness and safety of these drugs in the long run.

Zitieren

APA

Biswas, S., Smrity, S. Z., Bhuia, M. S., Sonia, F. A., Aktar, M. A., Chowdhury, R., Islam, T., Islam, M. T., Alencar, G. G., Paulo, C. L. R., Gurgel, A. P. A. D., & Coutinho, H. D. M. (2024). Beta-Thalassemia: A Pharmacological Drug-Based Treatment. Drugs and Drug Candidates, 3(1), 126-147. https://doi.org/10.3390/ddc3010008

Vancouver

Biswas S, Smrity SZ, Bhuia MS, Sonia FA, Aktar MA, Chowdhury R, et al. Beta-Thalassemia: A Pharmacological Drug-Based Treatment. Drugs and Drug Candidates. 2024;3(1):126-147. doi:10.3390/ddc3010008

BibTeX
@article{Biswas2024,
  author = {Biswas, Shrabonti and Smrity, Shanita Zaman and Bhuia, Md. Shimul and Sonia, Fatema Akter and Aktar, Mst. Asma and Chowdhury, Raihan and Islam, Tawhida and Islam, Muhammad Torequl and Alencar, Gabriel Gonçalves and Paulo, Cicera Laura Roque and Gurgel, Ana Pavla Almeida Diniz and Coutinho, Henrique Douglas Melo},
  title = {Beta-Thalassemia: A Pharmacological Drug-Based Treatment},
  journal = {Drugs and Drug Candidates},
  year = {2024},
  volume = {3},
  number = {1},
  pages = {126--147},
  doi = {10.3390/ddc3010008}
}
Kostenlos starten →